TransMedics Group, Inc. (TMDX) EPS Diluted: 4.87
Is TransMedics Group, Inc.’s EPS diluted high or low?
TransMedics Group, Inc.'s EPS diluted of 4.87 is 2509% above its 5-year average of 0.19, near the high end of its 5-year range (-1.60–4.87).
65.65% above its 12-month average of 2.94.
TMDX EPS Diluted Chart
TMDX Average EPS Diluted Chart
TMDX Current vs Average EPS Diluted Chart
TMDX EPS Diluted Metrics
EPS DILUTED
4.87
EPS DILUTED AVG TTM
2.94
EPS DILUTED AVG 3Y
0.97
EPS DILUTED AVG 5Y
0.19
EPS DILUTED AVG 10Y
N/A
EPS DILUTED AVG 15Y
N/A
EPS DILUTED AVG 20Y
N/A
CURRENT VS TTM AVG
+65.65%
CURRENT VS 3Y AVG
+402.06%
CURRENT VS 5Y AVG
+2508.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TransMedics Group, Inc. EPS Diluted Formula & Definition
EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. EPS Diluted FAQ
- What is the EPS diluted for TransMedics Group, Inc. (TMDX)?
- The EPS diluted for TMDX stock is 4.87.
- Is TransMedics Group, Inc.'s EPS diluted high or low?
- TransMedics Group, Inc.'s EPS diluted of 4.87 is 2509% above its 5-year average of 0.19, near the high end of its 5-year range (-1.60–4.87).
- What is the TTM average EPS diluted for TransMedics Group, Inc. (TMDX)?
- The TTM average EPS diluted for TMDX stock is 2.94.
- What is the 3Y average EPS diluted for TransMedics Group, Inc. (TMDX)?
- The 3Y average EPS diluted for TMDX stock is 0.97.
- What is the 5Y average EPS diluted for TransMedics Group, Inc. (TMDX)?
- The 5Y average EPS diluted for TMDX stock is 0.19.
TransMedics Group, Inc. EPS Diluted History
| DATE | EPS DILUTED |
|---|---|
| 2025-12-31 | 4.87 |
| 2024-12-31 | 1.01 |
| 2023-12-31 | -0.77 |
| 2022-12-31 | -1.23 |
| 2021-12-31 | -1.60 |
| 2020-12-31 | -1.16 |
| 2019-12-31 | -2.36 |
| 2018-12-31 | -1.23 |
| 2017-12-31 | -1.44 |
| 2016-12-31 | -1.66 |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein